Key Developments: Stentys SA (STEN.PA)

STEN.PA on Paris Stock Exchange

6.05EUR
6:54am EDT
Price Change (% chg)

€-0.10 (-1.63%)
Prev Close
€6.15
Open
€6.15
Day's High
€6.18
Day's Low
€5.96
Volume
36,707
Avg. Vol
36,239
52-wk High
€12.00
52-wk Low
€5.96

Search Stocks

Latest Key Developments (Source: Significant Developments)

Stentys signs first distribution agreements in South America
Wednesday, 9 Jul 2014 11:46am EDT 

Stentys SA:Signs first distribution contracts in Argentina, Chile and Colombia.Contracts signed within company strategy to expand commercial presence into Latin American coronary stent market.  Full Article

Stentys SA completes acquisition of Cappella Peel Away Inc
Thursday, 12 Jun 2014 01:00pm EDT 

Stentys SA:Says it presented the final terms of the acquisition of Cappella Peel Away Inc. and of its assets relating to a stent delivery system for a total amount of 1 million euro in stock and cash.  Full Article

Stentys SA to acquire Stent Delivery Technology
Wednesday, 4 Jun 2014 11:45am EDT 

Stentys SA:Signs acquisition agreement of Cappella Peel Away Inc. (Delaware, USA) and its assets relating to a stent delivery system.Financial terms were not disclosed.  Full Article

Stentys SA presented final results from APPOSITION IV study
Tuesday, 20 May 2014 07:15am EDT 

Stentys SA:Presented final results from APPOSITION IV study of its new Self-Apposing sirolimus-eluting stent (SES) during Hotline session at EuroPCR conference in Paris.APPOSITION IV enrolled 152 patients experiencing ST-elevation myocardial infarction (STEMI) and was first clinical trial to evaluate novel Self-Apposing sirolimus-eluting stent, which was compared to Medtronic`s Resolute zotarolimus-eluting stent at two different time points, 4 and 9 months.Evaluation was based on two imaging modalities, Quantitative Coronary Angiography (QCA) to measure difference in artery diameters between implantation and follow-up, and Optical Coherence Tomography (OCT).Results confirm that arteries with STENTYS SES healed faster than with balloon-expandable drug-eluting stents.At 9 months, STENTYS SES showed no reduction in artery lumen diameter (Late Lumen Loss of 0.04mm ± 0.43 under QCA) with near perfect arterial healing (99 pct covered struts at 9 months under OCT), demonstrating stent efficacy and safety.  Full Article

Stentys secures standby equity facility
Wednesday, 14 May 2014 11:45am EDT 

Stentys SA:Enters into standby equity facility with Societe Generale, exercisable by tranches at Stentys' discretion.At the request of Stentys, Societe Generale is committed to subscribe to successive capital increases over next 36 months, within global limit of 1,000,000 shares (i.e. 9.0 pct of the shares currently outstanding).For each tranche, issue price will equal volume weighted average share price of three trading days preceding effective date of purchase with discount capped at 5 pct.Stentys has no minimum drawdown obligation.  Full Article

Stentys SA's self-apposing stent featured in new article published by Journal of the American College of Cardiology
Tuesday, 29 Apr 2014 11:45am EDT 

Stentys SA:Says Journal of the American College of Cardiology (JACC) published paper entitled “Mechanisms, Pathophysiology, and Clinical Aspects of Incomplete Stent Apposition,” which highlights STENTYS’ Self-Apposing Stent among devices to minimize stent malapposition in clinical practice.Authors advise that devices, such as STENTYS’ Self-Apposing stent, which already demonstrated an early reduction of ISA compared with balloon-expandable stents during primary PCI, can reduce malapposition and potentially harmful consequences with which it is associated.  Full Article

Stentys to propose share repurchase program
Sunday, 20 Apr 2014 08:00pm EDT 

Stentys SA:To propose terms of share repurchase program to annual general meeting.Program would authorize repurchase of up to 10 pct of capital.Maximum price per share 35 euros.Total maximum that could be spent 38,978,502.50 euros.Authorization valid for 18 months.  Full Article

Stentys SA signs distribution partnerships in Asia
Wednesday, 8 Jan 2014 11:45am EST 

Stentys SA:Signs the first distribution partnerships for its stents in Asia with national distributors specialized in cardiovascular products in Singapore, Hong Kong and Malaysia.  Full Article

Stentys SA Announces Positive Results of Its OPEN II study of Self-Apposing Stent
Wednesday, 30 Oct 2013 12:45pm EDT 

Stentys SA announced positive results from the OPEN II study of its Self-Apposing Stent to treat acute myocardial infarction (AMI). OPEN II was a prospective, single-arm trial that enrolled 217 patients treated for chest pain due to a narrowing at a coronary artery bifurcation with the Company's paclitaxel-eluting stent in 21 hospitals in six European countries. The primary endpoint of MACE (composite of cardiac death, myocardial infarction, emergent by-pass surgery and target lesion revascularization) at six months was 10.1% for the whole study group, with a rate of 6.9% in patients with simple lesions. These results are favorably compared to the comparable trials in this area.  Full Article

Stentys SA Sirolimus-Eluting Stent Demonstrates Faster Arterial Healing Than Conventional Drug-Eluting Stent
Tuesday, 29 Oct 2013 12:45pm EDT 

Stentys SA announced that results from the 4-month arm of the APPOSITION IV study of its new Self-Apposing Sirolimus-eluting stent during the TCT (Transcatheter Cardiovascular Therapeutics) conference. The APPOSITION IV trial enrolled 152 patients suffering from ST-elevation Myocardial Infarction (STEMI) in a double-randomized trial to compare the STENTYS Sirolimus-eluting stent to Medtronic’s Resolute zotarolimus-eluting stent at two different time points, 4 and 9 months, evaluating stent apposition and strut coverage under intra-vascular OCT imaging (optical coherence tomography). Among the 62 patients enrolled in the 4-month group, those treated with a STENTYS stent had better apposition than the control stent (p=0.006). The imaging analysis also quantified the number of stent struts “covered” by tissue, an indication that the endothelium cells lining the artery wall have grown around the stent and that the vessel has healed. At 4 months, 32% of the STENTYS stents had all struts already covered compared to 4% for the Resolute (p=0.03).  Full Article

Search Stocks